Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials and To Provide an Update on Development Programs on May 6, 2021

Rhea-AI Summary

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced it will report its financial results and update on development programs pre-market on May 6, 2021. A conference call will be held the same day at 8:30 am ET, accessible by phone or via webcast. Financial results will be shared in an earnings press release available on Reata's website prior to the call. The audio of the call will be accessible for 90 days post-event. Reata focuses on developing therapeutics targeting metabolic and inflammatory pathways, with key candidates being bardoxolone methyl and omaveloxolone, which are still investigational.

PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on May 6, 2021.

Reata’s management will host a conference call on May 6, 2021 at 8:30 am ET. The conference call will be accessible by dialing (866) 270-1533 (toll-free domestic) or (412) 317-0797 (international) using the access code: 10153548. The webcast link is https://event.on24.com/wcc/r/3080993/647A7195D390CEF8F5FA6FFA73CD7C87.

First quarter 2021 financial results to be discussed during the call will be included in an earnings press release that will be available on the Company’s website shortly before the call at http://reatapharma.com/investors/ and will be available for 12 months after the call. The audio recording and webcast will be accessible for at least 90 days after the event at http://reatapharma.com/investors/.  

About Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Contact:
Reata Pharmaceuticals, Inc.
(972) 865-2219
http://reatapharma.com/ 

Investor Relations & Media:
Manmeet Soni (469) 299-9130
Andres Lorente (469) 442-4883
ir@reatapharma.com
media@reatapharma.com
http://www.reatapharma.com/contact-us/

Source: Reata Pharmaceuticals, Inc.

FAQ

When will Reata Pharmaceuticals report financial results for Q1 2021?

Reata Pharmaceuticals will report its Q1 2021 financial results pre-market on May 6, 2021.

What time is the Reata Pharmaceuticals conference call on May 6, 2021?

The conference call will be held at 8:30 am ET on May 6, 2021.

How can I access the Reata Pharmaceuticals conference call?

You can access the conference call by calling (866) 270-1533 for domestic or (412) 317-0797 for international participants.

Where can I find the financial results release for Reata Pharmaceuticals?

The financial results release will be available on Reata's website shortly before the call on May 6, 2021.

What are the main therapeutic candidates of Reata Pharmaceuticals?

Reata Pharmaceuticals' key therapeutic candidates are bardoxolone methyl and omaveloxolone.

Are bardoxolone and omaveloxolone approved for use?

No, bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established.